Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

FOREST' FISCAL 85 SALES OF DALALONE D.P., BANCAP HC WERE $5 2 mil., representing 20% of total sales and research revenues, the company announced in its recently issued 1985 annual report. The two products, which were acquired last fall when Forest purchased O'Neal, Jones & Feldman in an $8.3 mil. stock deal, helped boost corporate revenues to $25.8 mil., a 19.5% increase over the previous fiscal year ending March 31. In May the company announced its acquisition of Gilbert Labs for $10 mil. in Forest stock, and with it the headache combo Esgic. At the time of the Esgic acquisition, the product's sales volume was roughly $3 mil. annually. Referring to the growth potential for the three products, Forest President Howard Solomon noted: "We believe that growth potential can be accelerated. Esgic, for example, has never been detailed to physicians -- - its growth has been achieved solely through mail promotion. On the other hand, Dalalone D.P. and Bancap HC have not benefitted from mail promotion or a wide range of marketing techniques which are currently available." The report indicated that the U.S. sale of products under distribution and licensing arrangements with Upjohn, Sandoz and Syntex may begin soon. Paragraph"We hope that controlled release Mellaril, which we developed for Sandoz will be approved this year, and that our buccal nitroglycerin products will be marketed in the U.S. this year," the report stated. The latter product was recently declared DESI-effective for prevention and treatment of angina ("The Pink Sheet" July 8, T&G-4). "Next year may see approval for our long acting Motrin, followed by Ansaid, both nonsteroidal anti-inflammatories to be marketed by Upjohn," the company said. According to the report, Forest anticipates "several filings" with the FDA this year, with some products developed for other companies and some for marketing by the firm's 80-man detail force. The company maintains that Synchron, its controlled release technology, "continues to perform exceptionally well. . . we are currently setting up a program of expanded use with other active ingredients."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts